Hans Messner Allogeneic Transplant Program, Princess Margaret Hospital Cancer Centre, University Health Network, Toronto, Canada.
Department of Medicine, University of Toronto, Toronto, Canada.
Leuk Lymphoma. 2021 Sep;62(9):2193-2201. doi: 10.1080/10428194.2021.1910688. Epub 2021 Apr 8.
Allogeneic hematopoietic cell transplantation (HCT) can offer cure to some patients with acute lymphoblastic leukemia (ALL). It remains unclear how conditioning intensity affects transplant outcomes in ALL. In this retrospective study, we compared outcomes between 27 patients <60 who received reduced intensity conditioning (RIC) at Princess Margaret Hospital Cancer Center (PMCC) and 226 Cell Therapy Transplant Canada (CTTC) age-matched controls who received myeloablative conditioning (MAC) between 2007 and 2018. Compared to CTTC patients, PMCC patients had an inferior 2-y OS: 0.29 (95% CI: 0.11-0.49) vs 0.63 (0.56-0.70), HR = 2.10 (1.23-3.55), 0.006, higher TRM: 0.41 (0.22-0.60) vs 0.24 (0.18-0.30), HR = 2.00 (1.05-3.81), 0.04 and a trend toward increased risk of relapse: 0.36 (0.17-0.56) versus 0.17 (0.12-0.22), HR = 1.72 (0.82-3.62), 0.15. In multivariate analysis, RIC and the use of T-cell depletion (TCD) were associated with inferior OS. In ALL patients <60, the use of RIC with TCD is associated with inferior allogeneic HCT outcomes.
异基因造血细胞移植(HCT)可以为一些急性淋巴细胞白血病(ALL)患者提供治愈机会。目前尚不清楚预处理强度如何影响 ALL 患者的移植结果。在这项回顾性研究中,我们比较了 2007 年至 2018 年间在玛格丽特公主癌症中心(PMCC)接受低强度预处理(RIC)的 27 名<60 岁的患者和 226 名年龄匹配的接受清髓性预处理(MAC)的加拿大细胞治疗移植(CTTC)患者的结果。与 CTTC 患者相比,PMCC 患者的 2 年 OS 较差:0.29(95%CI:0.11-0.49)比 0.63(0.56-0.70),HR=2.10(1.23-3.55),P=0.006,TRM 更高:0.41(0.22-0.60)比 0.24(0.18-0.30),HR=2.00(1.05-3.81),P=0.04,且复发风险呈增加趋势:0.36(0.17-0.56)比 0.17(0.12-0.22),HR=1.72(0.82-3.62),P=0.15。多变量分析显示,RIC 和 T 细胞耗竭(TCD)的使用与 OS 较差相关。在<60 岁的 ALL 患者中,RIC 联合 TCD 的使用与异基因 HCT 结局较差相关。